Phaseline

Companies › RemeGen

RemeGen: clinical trials, targets and expected readouts

8 active drug programs in 252 registered trials: 172 Phase 2, 54 Phase 3, 22 Phase 1, 4 Phase 4; Oncology, Other, Genitourinary, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Disitamab Vedotin
Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin disrupting agent
ERBB2, TubulinPhase 3Urothelial Carcinoma; Breast Cancer; Gastric Carcinoma; Gastric Cancer …Dec 2026
Toripalimab (JS001)
Programmed cell death protein 1 antagonist
PDCD1Phase 3Urothelial Carcinoma; Gastric Cancer; Breast Cancer; Biliary Tract Cancer (BTC) …Dec 2026
Telitacicept–Phase 3Primary IgA Nephropathy; Myasthenia Gravis, Ocular; ANCA Associated Vasculitis; ANCA-associated Vasculitis …Dec 2026
RC148
Monoclonal antibody targeting unknown oncology target
–Phase 3Non-Small Cell Lung Cancer; Colorectal (Colon or Rectal) Cancer; Breast Cancer; Solid TumorMay 2027
RC108
MET-targeted therapy
–Phase 2Non-Small Cell Lung CancerDec 2027
RC278–Phase 1Solid TumorsDec 2027
RC288 For Injection–Phase 1Solid TumorsDec 2029
RC118-ADC
Anti-CLDN18.2 antibody-drug conjugate with microtubule inhibitor payload
CLDN18Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03930498Toripalimab (JS001)Phase 2Recurrent Nasopharyngeal CarcinomaOncologyNov 2023
NCT05555888Toripalimab (JS001)Phase 2Early Low Rectal CancerOncologyMar 2024
NCT05586061Disitamab VedotinPhase 2HER2-positive Gastric CancerOncologyDec 2024
NCT05586100Toripalimab (JS001)Phase 2Patients With Locally Recurrent Resectable Head and Neck Squamous Cell CarcinomaOncologyApr 2025
NCT07098897TelitaciceptPhase 3IgA Nephropathy (IgAN)GenitourinaryMay 2025
NCT05980481Disitamab VedotinPhase 2Gastric CancerOncologyJul 2025
NCT05980481Toripalimab (JS001)Phase 2Gastric CancerOncologyJul 2025
NCT06020755Toripalimab (JS001)Phase 2Gestational Trophoblastic NeoplasiaOtherAug 2025
NCT05205850RC118-ADCPhase 1Advanced Solid TumorOncologySep 2025
NCT06020885Toripalimab (JS001)Phase 1Esophageal Squamous Cell CarcinomaOncologyOct 2025
NCT07065435Disitamab VedotinPhase 2HER2 + Breast CancerOncologyDec 2025
NCT05998759TelitaciceptPhase 2Connective Tissue DiseasesHematologyDec 2025
NCT06293690Toripalimab (JS001)Phase 2Non-small Lung CancerOncologyDec 2025
NCT06016062RC148Phase 1Solid TumorOncologyDec 2025
NCT05147844Toripalimab (JS001)Phase 2Nasopharyngeal CarcinomaOncologyDec 2025
NCT05799287TelitaciceptPhase 3Primary IgA NephropathyGenitourinaryJun 2026
NCT06852287Toripalimab (JS001)Phase 2Intrahepatic Cholangiocarcinoma (Icc)OncologySep 2026
NCT07353723Toripalimab (JS001)Phase 2Head & Neck CancerOncologyNov 2026
NCT06462222Toripalimab (JS001)Phase 1Leptomeningeal MetastasisOncologyNov 2026
NCT05943379Disitamab VedotinPhase 2NMIBCOncologyDec 2026
NCT06426511Toripalimab (JS001)Phase 2Lung Cancer, Nonsmall CellOncologyDec 2026
NCT06151743Toripalimab (JS001)Phase 2Locally Advanced Hypopharyngeal CarcinomaOncologyDec 2026
NCT07446452Disitamab VedotinPhase 2HER2-low Breast CancerOncologyDec 2026
NCT06178159Disitamab VedotinPhase 2Breast CancerOncologyDec 2026
NCT06227117Disitamab VedotinPhase 2Breast CancerOncologyDec 2026
NCT06221748Disitamab VedotinPhase 2Gastric CancerOncologyDec 2026
NCT06178159Toripalimab (JS001)Phase 2Breast CancerOncologyDec 2026
NCT06227117Toripalimab (JS001)Phase 2Breast CancerOncologyDec 2026
NCT03907826Toripalimab (JS001)Phase 3Recurrent Nasopharyngeal CarcinomaOncologyDec 2026
NCT05340491Toripalimab (JS001)Phase 3Nasopharyngeal CarcinomaOncologyDec 2026
NCT06323239Toripalimab (JS001)Phase 2Nasopharyngeal CarcinomaOncologyDec 2026
NCT06525428Toripalimab (JS001)Phase 2Microsatellite Stable Metastatic Colorectal CancerOncologyDec 2026
NCT06914440Toripalimab (JS001)Phase 2Breast CancerOncologyDec 2026
NCT04669496Toripalimab (JS001)Phase 2Intrahepatic CholangiocarcinomaOncologyDec 2026
NCT06201065Toripalimab (JS001)Phase 3Hepatocellular CarcinomaOncologyDec 2026
NCT05912816Disitamab VedotinPhase 2Upper Urinary Tract Urothelial CarcinomaOncologyDec 2026
NCT07093866Disitamab VedotinPhase 2mCRPCOncologyDec 2026
NCT06505837Toripalimab (JS001)Phase 3Recurrent Metastatic Non-Squamous Non Small Cell Lung CancerOncologyDec 2026
NCT06505837Toripalimab (JS001)Phase 3Recurrent Metastatic Non-Squamous Non Small Cell Lung CancerOncologyDec 2026
NCT06354231Toripalimab (JS001)Phase 2Renal InsufficiencyGenitourinaryDec 2026
NCT05125055Toripalimab (JS001)Phase 2Oral Squamous Cell CarcinomaOncologyDec 2026
NCT05768464Toripalimab (JS001)Phase 2Non-clear Renal Cell CarcinomaOncologyDec 2026
NCT05302284Disitamab VedotinPhase 3Urothelial CarcinomaOncologyDec 2026
NCT06389006Disitamab VedotinPhase 2Breast CancerOncologyDec 2026
NCT06730373Disitamab VedotinPhase 2HER2-positive Gastric CancerOncologyDec 2026
NCT06992362Disitamab VedotinPhase 2Hepatoid Adenocarcinoma of StomachOncologyDec 2026
NCT06572319Disitamab VedotinPhase 1HER2-positive Gastric CancerOncologyDec 2026
NCT07249632TelitaciceptPhase 3Myasthenia Gravis, OcularNeurologyDec 2026
NCT05962840TelitaciceptPhase 4ANCA Associated VasculitisImmunologyDec 2026
NCT05965284TelitaciceptPhase 4ANCA-associated VasculitisImmunologyDec 2026
NCT05302284Toripalimab (JS001)Phase 3Urothelial CarcinomaOncologyDec 2026
NCT06389006Toripalimab (JS001)Phase 2Breast CancerOncologyDec 2026
NCT04523493Toripalimab (JS001)Phase 3Advanced Hepatocellular Carcinoma (HCC)OncologyDec 2026
NCT05975307Toripalimab (JS001)Phase 2Muscle-Invasive Bladder CarcinomaOncologyDec 2026
NCT05173246Toripalimab (JS001)Phase 2Esophageal Small Cell CarcinomaOncologyDec 2026
NCT06187597Toripalimab (JS001)Phase 2Locally Advanced Esophageal Squamous Cell CarcinomaOncologyDec 2026
NCT03859128Toripalimab (JS001)Phase 2Hepatocellular CarcinomaOncologyDec 2026
NCT04517214Toripalimab (JS001)Phase 2Nasopharyngeal CarcinomaOncologyDec 2026
NCT06690697Toripalimab (JS001)Phase 2Clear Cell Renal Cell CarcinomaOncologyDec 2026
NCT05798845Toripalimab (JS001)Phase 2NSCLCOncologyDec 2026

The 60 nearest readouts of 252 trials; the rest in the app.

Targets

ERBB2 (1) Tubulin (1) CLDN18 (1) PDCD1 (1)

Companies with the same targets

Roche Beijing Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Innovent Biologics (Suzhou) Akeso Sichuan Kelun-Biotech Biopharmaceutical

Companies built like this

CSPC Megalith Biopharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Bio-Thera Solutions Dizal Pharmaceuticals BioRay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.